Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation — GERN
For best results when printing this announcement, please click on link below: Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation — GERN Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti ( ), LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS: GERN). Throughout 2024, the Company touted the revenue outlook and anticipated growth of its primary product, imetelstat, a telomerase inhibitor that it sells under the brand name, Rytelo, designed to reduce the proliferation of malignant cells to permit the production of new healthy cells. On February 26, 2025, the Company announced its financial results for the fourth quarter of fiscal 2024, disclosing that the growth of Rytelo had flattened over the prior months due to seasonality, competition, lack of awareness, and the burden of the monitoring requirement necessary for the drug treatment. Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material
For best results when printing this announcement, please click on link below: Geron Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Geron Corporation — GERN Former Attorney General of Louisiana, Charles C. , a partner at the law firm of Kahn Swick & Foti ( ), LLC (“KSF”), announces that KSF has commenced an investigation into Geron Corporation (“Geron” or the “Company”) (NasdaqGS: GERN).
Throughout 2024, the Company touted the revenue outlook and anticipated growth of its primary product, imetelstat, a telomerase inhibitor that it sells under the brand name, Rytelo, designed to reduce the proliferation of malignant cells to permit the production of new healthy cells. On February 26, 2025, the Company announced its financial results for the fourth quarter of fiscal 2024, disclosing that the growth of Rytelo had flattened over the prior months due to seasonality, competition, lack of awareness, and the burden of the monitoring requirement necessary for the drug treatment.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws, which remains ongoing. KSF’s investigation is focusing on whether Geron’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws. com) ), or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C.
, is one of the nation’s premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors — in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
, Suite 960 New Orleans, LA 70163